---
id: hepatobiliary-infections_091
category: clinical_syndromes
tags: [cholangitis, cholecystitis, liver-abscess, ERCP, Tokyo-guidelines]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Hepatobiliary Infections

**Q:** What are the clinical features, microbiology, and management of acute cholangitis, cholecystitis, and pyogenic liver abscess?

**A:**

## 1. ACUTE CHOLANGITIS

**Definition:**
- **Acute Cholangitis:** Infection of bile ducts, typically due to biliary obstruction
- **Most common cause:** Choledocholithiasis (common bile duct stones)

---

### **Epidemiology & Risk Factors:**

**Causes of Obstruction:**
- **Choledocholithiasis** (CBD stones) - most common
- **Malignant obstruction** (pancreatic cancer, cholangiocarcinoma)
- **Benign strictures** (post-surgical, PSC)
- **Post-ERCP**

---

### **Microbiology:**

**Most Common Organisms:**

| **Organism** | **Frequency** | **Source** |
|--------------|---------------|------------|
| ***E. coli*** | **25-50%** (#1) | GI flora |
| ***Klebsiella* species** | **15-20%** | GI flora |
| ***Enterococcus* species** | **10-20%** | GI flora |
| **Anaerobes** (*Bacteroides*, *Clostridium*) | **10-15%** | GI flora (more common if biliary-enteric anastomosis) |
| ***Pseudomonas aeruginosa*** | **<5%** | Post-ERCP, biliary stents |

**Polymicrobial:** 50% (often mixed aerobes + anaerobes)

**Key Point:** ***E. coli* = #1 pathogen** (25-50%), polymicrobial in 50%

---

### **Clinical Presentation:**

**Charcot Triad (50-70% Have All Three):**
- **Fever** (most common - 90%)
- **Jaundice** (60-70%)
- **Right upper quadrant (RUQ) pain** (70%)

**Reynolds Pentad (Severe/Suppurative Cholangitis - 10-20%):**
- **Charcot triad**
  **PLUS**
- **Altered mental status** (sepsis)
- **Hypotension** (septic shock)

**Key Point:** **Charcot triad = fever + jaundice + RUQ pain** (cholangitis)

---

### **Diagnosis:**

**Laboratory:**
- **↑ Bilirubin** (direct/conjugated)
- **↑ Alkaline phosphatase** (cholestatic pattern)
- **↑ WBC** (leukocytosis)
- **Blood cultures positive:** 20-70%

**Imaging:**

**Ultrasound (RUQ):**
- **Dilated bile ducts** (>7 mm common bile duct)
- **Stones** (may not visualize CBD stones well)

**CT Abdomen/Pelvis (Contrast):**
- **Dilated intrahepatic/extrahepatic bile ducts**
- **Identify level of obstruction**

**MRCP (Magnetic Resonance Cholangiopancreatography):**
- **Best non-invasive imaging** for biliary tree
- **Visualizes stones, strictures, anatomy**

---

### **Severity Grading (2018 Tokyo Guidelines):**

| **Grade** | **Criteria** | **Management** |
|-----------|--------------|----------------|
| **Grade I (Mild)** | No organ dysfunction | Antibiotics + ERCP (elective within 48-72h) |
| **Grade II (Moderate)** | ≥2 of: WBC <4 or >12, fever ≥39°C, age >75, bilirubin >5, albumin <2.5 | Antibiotics + **Early ERCP (<24h)** |
| **Grade III (Severe)** | ≥1 organ dysfunction (shock, altered MS, respiratory failure, renal failure, liver failure, coagulopathy) | **Urgent biliary drainage (<24h)** + ICU |

---

### **Treatment:**

---

#### **Step 1: Resuscitation + Antibiotics (IMMEDIATELY)**

**Empiric Antibiotics:**

**Mild-Moderate (Community-Acquired):**

| **Agent** | **Dosing** |
|-----------|------------|
| **Ceftriaxone** OR **Cefotaxime** | 1-2g IV q24h OR 1-2g IV q8h |
| **PLUS (If severe or biliary-enteric anastomosis)** | |
| **Metronidazole** | 500 mg IV q8h |

**Severe or Healthcare-Associated:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Piperacillin-tazobactam** | 3.375-4.5g IV q6-8h |
| **OR Meropenem** OR **Imipenem** | 1g IV q8h OR 500 mg IV q6h |

**Alternative (PCN Allergy):**
- **Ciprofloxacin** 400 mg IV q12h + **Metronidazole** 500 mg IV q8h

**Key Point:** **Ceftriaxone (± metronidazole) = first-line** for community-acquired

---

#### **Step 2: Biliary Drainage (DEFINITIVE TREATMENT)**

**Modalities:**

**ERCP (Endoscopic Retrograde Cholangiopancreatography):**
- **First-line** for drainage
- **Stone extraction, stent placement**
- **Timing:**
  - **Urgent (<24h):** Severe cholangitis (Grade III)
  - **Early (<24-48h):** Moderate cholangitis (Grade II)
  - **Elective (48-72h):** Mild cholangitis (Grade I)

**Percutaneous Transhepatic Cholangiography (PTC):**
- If ERCP fails or not feasible

**Surgical Drainage:**
- Last resort (if ERCP/PTC fail)

**Key Point:** **Biliary drainage = definitive treatment** (antibiotics alone insufficient)

---

#### **Duration of Antibiotics:**

- **3-5 days** (after successful drainage + clinical improvement)
- **7-10 days** (if slow response or inadequate drainage)

---

## 2. ACUTE CHOLECYSTITIS

**Definition:**
- **Acute Cholecystitis:** Inflammation of gallbladder, typically due to **cystic duct obstruction** (gallstone)

---

### **Epidemiology:**

**Types:**
- **Calculous cholecystitis** (90-95%) - gallstone obstruction
- **Acalculous cholecystitis** (5-10%) - critically ill, post-op, TPN

---

### **Microbiology:**

**Organisms (Similar to Cholangitis):**
- ***E. coli***, *Klebsiella*, *Enterococcus*, anaerobes (*Bacteroides*, *Clostridium*)
- **50% are sterile** (chemical inflammation, not infection)

---

### **Clinical Presentation:**

**Murphy Sign:**
- **Inspiratory arrest** during palpation of RUQ (patient stops breathing in due to pain)
- **Sensitivity 50-60%**, specificity 80%

**Symptoms:**
- **RUQ pain** (may radiate to right shoulder)
- **Fever** (50%)
- **Nausea/vomiting**
- **Jaundice** (if Mirizzi syndrome or concurrent cholangitis)

---

### **Diagnosis:**

**Laboratory:**
- **↑ WBC** (leukocytosis)
- **Mild ↑ bilirubin, ↑ ALP** (if Mirizzi syndrome)
- **Normal bilirubin** in most cases (vs cholangitis with jaundice)

**Imaging:**

**Ultrasound (RUQ) - FIRST-LINE:**
- **Gallstones** (echogenic with posterior shadowing)
- **Gallbladder wall thickening** (>3-4 mm)
- **Pericholecystic fluid**
- **Sonographic Murphy sign** (tenderness over gallbladder with probe)

**HIDA Scan (Hepatobiliary Iminodiacetic Acid):**
- **Non-filling of gallbladder** = cystic duct obstruction
- **Sensitivity/specificity >95%** (if ultrasound equivocal)

**CT Abdomen/Pelvis:**
- **Gallbladder wall thickening**, pericholecystic fluid, fat stranding
- **Useful for complications** (perforation, abscess, emphysematous cholecystitis)

---

### **Treatment:**

---

#### **Medical Management:**

**Antibiotics:**

**Mild-Moderate (Community-Acquired):**
- **Ceftriaxone** 1-2g IV q24h + **Metronidazole** 500 mg IV q8h

**Severe or Healthcare-Associated:**
- **Piperacillin-tazobactam** 3.375-4.5g IV q6-8h
- **OR Meropenem** 1g IV q8h

**Duration:**
- **3-5 days** (after cholecystectomy)
- **7-10 days** (if no surgery, clinical improvement)

---

#### **Surgical Management:**

**Cholecystectomy (Definitive Treatment):**

**Timing:**
- **Early cholecystectomy (<72h):** **Preferred** (reduces complications, hospital stay)
- **Delayed cholecystectomy (6-8 weeks):** If high surgical risk, allow inflammation to resolve first

**Laparoscopic vs Open:**
- **Laparoscopic preferred** (lower morbidity)
- **Convert to open** if complications (perforation, abscess, gangrene)

---

**Percutaneous Cholecystostomy (If Not Surgical Candidate):**
- **Tube drainage** for critically ill, high surgical risk
- **Bridge to surgery** or **definitive** (if never becomes surgical candidate)

---

### **Complications:**

**Gangrenous Cholecystitis:**
- **Gallbladder wall necrosis**
- **Higher perforation risk**
- **Urgent surgery**

**Emphysematous Cholecystitis:**
- **Gas-forming organisms** (*Clostridium*, *E. coli*, *Klebsiella*)
- **Diabetics, elderly**
- **CT: Gas in gallbladder wall**
- **Urgent surgery**

**Perforation:**
- **Biliary peritonitis**
- **Emergency surgery**

---

## 3. PYOGENIC LIVER ABSCESS

**Definition:**
- **Pyogenic Liver Abscess:** Bacterial infection within liver parenchyma (pus-filled cavity)

---

### **Epidemiology:**

**Incidence:**
- **~2-3 per 100,000** (increasing in developed countries)
- **More common in Asia** (Klebsiella liver abscess syndrome)

**Risk Factors:**
- **Biliary disease** (cholangitis, cholecystitis) - #1 cause
- **Diabetes mellitus**
- **Malignancy** (colorectal cancer, pancreatic cancer)
- **Immunosuppression**
- **Portal pyemia** (diverticulitis, appendicitis, IBD)
- **Trauma**
- **Cryptogenic** (30-50% - no identifiable source)

---

### **Microbiology:**

**Most Common Organisms:**

| **Organism** | **Frequency** | **Key Features** |
|--------------|---------------|------------------|
| ***E. coli*** | **30-40%** | GI/biliary source |
| ***Klebsiella pneumoniae*** | **20-30%** | **#1 in Asia** (invasive K1/K2 serotypes)<br>**Klebsiella liver abscess syndrome** |
| ***Streptococcus anginosus* group** | **10-20%** | Abscess formation (brain, liver, lung) |
| **Anaerobes** (*Bacteroides*, *Fusobacterium*) | **10-20%** | Biliary source, polymicrobial |
| ***Enterococcus* species** | **5-10%** | Biliary source |

**Polymicrobial:** 30-50%

**Key Point:** ***E. coli* = #1 in Western countries**, ***Klebsiella* = #1 in Asia**

---

### ***Klebsiella pneumoniae* Liver Abscess Syndrome (Asia-Pacific):**

**Clinical Features:**
- **Community-acquired**
- **Diabetes mellitus** (50-70%)
- **Monomicrobial** *K. pneumoniae* (hypermucoviscous K1/K2 serotypes)
- **Metastatic complications** (20-30%):
  - **Endophthalmitis** (endogenous - vision-threatening)
  - **Meningitis**
  - **Necrotizing fasciitis**

**Key Point:** ***Klebsiella* liver abscess → Check for endophthalmitis** (ophthalmology consult)

---

### **Clinical Presentation:**

**Symptoms:**
- **Fever** (90%)
- **RUQ pain** (50-70%)
- **Nausea/vomiting**
- **Weight loss** (if subacute/chronic)
- **Jaundice** (20-30% - if biliary obstruction)

**Physical Exam:**
- **RUQ tenderness**
- **Hepatomegaly**

---

### **Diagnosis:**

**Laboratory:**
- **↑ WBC** (leukocytosis)
- **↑ ALP** (cholestatic)
- **Mild ↑ bilirubin** (if biliary obstruction)
- **↑ CRP, ESR**
- **Blood cultures positive:** 50-70%

**Imaging:**

**CT Abdomen/Pelvis (Contrast) - GOLD STANDARD:**
- **Hypodense lesion** with **peripheral rim enhancement** ("target sign")
- **Gas-forming abscess** (if *E. coli*, *Klebsiella*, anaerobes)
- **Multiple lesions** (30%)

**Ultrasound (RUQ):**
- **Hypoechoic lesion**
- **Good for initial screening**, but **CT superior** for characterization

---

### **Treatment:**

---

#### **Step 1: Antibiotics (Empiric)**

**Community-Acquired:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Ceftriaxone** OR **Cefotaxime** | 2g IV q12-24h OR 2g IV q8h |
| **PLUS** | |
| **Metronidazole** | 500 mg IV q8h |

**Healthcare-Associated or Severe:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Piperacillin-tazobactam** | 3.375-4.5g IV q6-8h |
| **OR Meropenem** | 1g IV q8h |

**Duration:**
- **4-6 weeks** (IV → PO step-down after clinical improvement)
- **Consider longer if slow response or incomplete drainage**

---

#### **Step 2: Drainage (Essential for Abscesses >5 cm)**

**Indications:**
- **Abscess ≥5 cm**
- **Persistent fever despite antibiotics**
- **Concern for rupture**

**Modalities:**

**Percutaneous Drainage (Preferred):**
- **Ultrasound-guided or CT-guided**
- **Catheter placement** (leave in until drainage <10-20 mL/day)

**Surgical Drainage:**
- If percutaneous drainage fails
- If multiloculated abscess
- If ruptured abscess (peritonitis)

**Antibiotics Alone:**
- If abscess **<5 cm** AND **clinically improving**
- **NOT recommended for large abscesses** (high failure rate)

---

#### **Step 3: Identify and Treat Underlying Source:**

**Workup:**
- **Colonoscopy** (if age >50 or colorectal cancer risk factors)
- **MRCP or ERCP** (if biliary source suspected)
- **Assess for intra-abdominal pathology** (diverticulitis, appendicitis)

---

### **Prognosis:**

**Mortality:**
- **10-20%** (with treatment)
- **Higher mortality:** Age >65, diabetes, septic shock, *Klebsiella* (if metastatic complications)

**Predictors of Poor Outcome:**
- **Multiple abscesses**
- **Septic shock**
- **Inadequate drainage**
- **Malignancy**

---

**Mnemonic: "Charcot Triad = Fever + Jaundice + RUQ Pain"**
- **C**holangitis
- **F**ever (most common)
- **J**aundice
- **RUQ** pain

**Mnemonic: "Reynolds Pentad = Charcot + Shock + Confusion"**
- **R**eynolds = severe cholangitis
- Charcot triad + **S**hock + **C**onfusion (altered mental status)

**Mnemonic: "ERCP Drains Cholangitis"**
- **E**RCP = definitive treatment (drainage)
- **D**rainage essential (antibiotics alone insufficient)

**Clinical Pearls:**
- **Cholangitis: Charcot triad = fever + jaundice + RUQ pain** (50-70% have all three)
- **Reynolds pentad = severe cholangitis** (Charcot + shock + altered MS)
- ***E. coli* = #1 pathogen** in cholangitis, cholecystitis, liver abscess (Western countries)
- **ERCP = definitive treatment for cholangitis** (antibiotics alone insufficient)
- **Tokyo guidelines:** Urgent ERCP <24h for severe cholangitis
- **Cholecystitis: Early cholecystectomy (<72h) preferred** (reduces complications)
- **Murphy sign:** Inspiratory arrest during RUQ palpation (cholecystitis)
- **Pyogenic liver abscess:** Drainage essential if ≥5 cm
- ***Klebsiella* liver abscess syndrome:** Diabetes, metastatic complications (endophthalmitis, meningitis)
- **Check for endophthalmitis** if *Klebsiella* liver abscess (vision-threatening)
- **Antibiotics x 4-6 weeks** for liver abscess

**Media:** None

**Sources:** [Tokyo Guidelines 2018 - Acute cholangitis/cholecystitis], [Clinical Infectious Diseases 2024 - Pyogenic liver abscess], [NEJM 2023 - Biliary tract infections], [Hepatology 2024 - Klebsiella liver abscess syndrome], [Surgery 2024 - Early cholecystectomy outcomes]
